A biologic candidate developed by a Japanese global pharmaceutical company and manufactured at Ajinomoto Althea using its CORYNEX Protein Expression System, has entered Phase I trials. The CORYNEX system is a protein expression platform that combines attributes of mammalian and microbial systems to simplify processes to produce and purify recombinant proteins with reduced production costs and greater speed. The system utilizes a gram-positive bacterium, Corynebacterium glutamicum, to produce...